Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease
Objective: To evaluate the association between serum insulin-like growth factor binding protein 2 (IGFBP2) and the degree of hepatic steatosis in patients with MASLD. Methods: A total of 347 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were enrolled, adhering to the...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-07-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0285.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850098215771176960 |
|---|---|
| author | Ziwei Wang Hongyan Wu Hsiuying Fu Yingying Xue Lixuan Shen Jingyu Zhu Ziwei Zhu Xizhong Yu Ruonan Zhou Wenbin Shang |
| author_facet | Ziwei Wang Hongyan Wu Hsiuying Fu Yingying Xue Lixuan Shen Jingyu Zhu Ziwei Zhu Xizhong Yu Ruonan Zhou Wenbin Shang |
| author_sort | Ziwei Wang |
| collection | DOAJ |
| description | Objective: To evaluate the association between serum insulin-like growth factor binding protein 2 (IGFBP2) and the degree of hepatic steatosis in patients with MASLD. Methods: A total of 347 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were enrolled, adhering to the inclusion criteria. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were measured by FibroScan, while serum IGFBP2 levels were quantified by ELISA. Hepatic IGFBP2 mRNA expression data were obtained from the Gene Expression Omnibus database (GEO database). Levels of serum IGFBP2 and hepatic IGFBP2 mRNA between healthy controls and MASLD patients were separately compared. Correlation analyses were performed to evaluate the relationships between CAP and IGFBP2. Results: Both the serum IGFBP2 levels and the hepatic IGFBP2 mRNA expression were significantly higher in patients with MASLD compared with healthy individuals. In patients with MASLD, the serum IGFBP2 level showed an inverse correlation with CAP values (r = −0.133, P < 0.05) and was identified as an independent determinant of hepatic steatosis (β = −0.104, P < 0.05), while no significant association was observed between LSM and IGFBP2 (P > 0.05). Conclusion: In patients with MASLD, IGFBP2 may exert a protective effect against hepatic steatosis progression but appears to play a negligible role in fibrogenesis. |
| format | Article |
| id | doaj-art-59cd2edbe0114c97892d3dba5dd4dc09 |
| institution | DOAJ |
| issn | 2049-3614 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj-art-59cd2edbe0114c97892d3dba5dd4dc092025-08-20T02:40:47ZengBioscientificaEndocrine Connections2049-36142025-07-0114710.1530/EC-25-02851Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver diseaseZiwei Wang0Hongyan Wu1Hsiuying Fu2Yingying Xue3Lixuan Shen4Jingyu Zhu5Ziwei Zhu6Xizhong Yu7Ruonan Zhou8Wenbin Shang9Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaKey Laboratory for Metabolic Diseases in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaObjective: To evaluate the association between serum insulin-like growth factor binding protein 2 (IGFBP2) and the degree of hepatic steatosis in patients with MASLD. Methods: A total of 347 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were enrolled, adhering to the inclusion criteria. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were measured by FibroScan, while serum IGFBP2 levels were quantified by ELISA. Hepatic IGFBP2 mRNA expression data were obtained from the Gene Expression Omnibus database (GEO database). Levels of serum IGFBP2 and hepatic IGFBP2 mRNA between healthy controls and MASLD patients were separately compared. Correlation analyses were performed to evaluate the relationships between CAP and IGFBP2. Results: Both the serum IGFBP2 levels and the hepatic IGFBP2 mRNA expression were significantly higher in patients with MASLD compared with healthy individuals. In patients with MASLD, the serum IGFBP2 level showed an inverse correlation with CAP values (r = −0.133, P < 0.05) and was identified as an independent determinant of hepatic steatosis (β = −0.104, P < 0.05), while no significant association was observed between LSM and IGFBP2 (P > 0.05). Conclusion: In patients with MASLD, IGFBP2 may exert a protective effect against hepatic steatosis progression but appears to play a negligible role in fibrogenesis.https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0285.xmlmetabolic dysfunction-associated steatotic liver diseaseinsulin-like growth factor binding protein 2liver fibrosishepatic steatosis |
| spellingShingle | Ziwei Wang Hongyan Wu Hsiuying Fu Yingying Xue Lixuan Shen Jingyu Zhu Ziwei Zhu Xizhong Yu Ruonan Zhou Wenbin Shang Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease Endocrine Connections metabolic dysfunction-associated steatotic liver disease insulin-like growth factor binding protein 2 liver fibrosis hepatic steatosis |
| title | Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease |
| title_full | Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease |
| title_fullStr | Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease |
| title_full_unstemmed | Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease |
| title_short | Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease |
| title_sort | serum insulin like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction associated steatotic liver disease |
| topic | metabolic dysfunction-associated steatotic liver disease insulin-like growth factor binding protein 2 liver fibrosis hepatic steatosis |
| url | https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0285.xml |
| work_keys_str_mv | AT ziweiwang seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT hongyanwu seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT hsiuyingfu seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT yingyingxue seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT lixuanshen seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT jingyuzhu seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT ziweizhu seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT xizhongyu seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT ruonanzhou seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease AT wenbinshang seruminsulinlikegrowthfactorbindingprotein2isassociatedwithhepaticsteatosisinadultswithmetabolicdysfunctionassociatedsteatoticliverdisease |